Extended stage small cell lung cancer patients confirmed histologically in full, partial or stable response after platinum-etoposide chemo-immunotherapy candidate to maintenance immunotherapy with Durvalumab.
Conditions
Brief summary
The assessment of 12-Months progression-free survival (PFS, defined as time from enrollment to the date of objective disease progression both locoregionally and/or systemically) or death for any cause in absence of progression of disease) in extensive stage SCLC patients
Detailed description
Overall survival, Loco-regional control, Metastasis-free survival, Overall response rate, Acute toxicity, Late toxicity, General security profile, Quality of life
Interventions
DRUGDURVALUMAB
Sponsors
Azienda Ospedaliero Universitaria Di Modena
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The assessment of 12-Months progression-free survival (PFS, defined as time from enrollment to the date of objective disease progression both locoregionally and/or systemically) or death for any cause in absence of progression of disease) in extensive stage SCLC patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Loco-regional control, Metastasis-free survival, Overall response rate, Acute toxicity, Late toxicity, General security profile, Quality of life | — |
Countries
Italy
Outcome results
None listed